ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1535

Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis

Aya Kawasaki1, Naoya Inoue1, Chihiro Ajimi1, Ikue Ito1, Ken-ei Sada2, Shigeto Kobayashi3, Hidehiro Yamada4, Hiroshi Furukawa5, Makoto Tomita6, Takayuki Sumida7, Shigeto Tohma8, Nobuyuki Miyasaka9, Shoichi Ozaki4, Hiroshi Hashimoto10, Hiroshi Makino2, Masayoshi Harigai11 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Internal Medicine, St. Marianna University, Kawasaki, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 6Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 8Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, 9Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 10Juntendo University School of Medicine, Tokyo, Japan, 11Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: ANCA, genomics and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), geographic difference in the type of vasculitis is well known. While granulomatosis with polyangiitis (GPA) is the most common form of AAV in northern European populations, microscopic polyangiitis (MPA) accounts for the majority of AAV in Japan, suggesting that the genetic background may play a role in the occurrence of these diseases. Due to low prevalence in European populations, little is known on the genetics of MPA or myeloperoxidase (MPO)-ANCA positive vasculitis. We started a multicenter collaborative study on the genetics of AAV in a Japanese population in 1999. Thus far, we reported a significant association of HLA-DRB1*09:01 with MPA. HLA-DRB1*09:01, one of the most common HLA-DRB1 alleles in the Asian but rare in the Caucasian populations, has been shown to be associated with multiple autoimmune diseases in Japan.

We have also demonstrated that STAT4, IRF5 and BLK were associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc) in a Japanese population, indicating that these genes are shared susceptibility genes to multiple autoimmune diseases. Thus far, association between these genes and MPA or MPO-ANCA positive vasculitis has not been reported. In this study, we examined association of these genes with Japanese AAV, mainly consisting of MPO-ANCA positive vasculitis.

Methods:

Association of STAT4 rs7574865, IRF5 rs2280714 and BLK rs13277113, all previously shown to be associated with other autoimmune diseases in a Japanese population, was examined in 177 Japanese patients with AAV including 127 MPA, 31 GPA and 14 eosinophilic granulomatosis with polyangiitis (EGPA), as well as in 511 healthy individuals. Among the patients, 155 were positive for MPO-ANCA. The genotypes were determined using TaqMan genotyping assay and direct sequencing.

Results:

The frequency of STAT4 rs7574865 T/T genotype, the risk genotype for SLE, RA and SSc, was significantly increased in MPO-ANCA positive patients (18.7%) as compared with healthy controls (10.4%, P=0.0058, odds ratio [OR] 1.98, 95% condidence interval [CI] 1.22-3.23). A tendency toward association was also observed in MPA (16.5%, P=0.053, OR 1.71, 95%CI 0.99-2.94), GPA (P=0.12, OR 2.07, 95%CI 0.83-5.18) and EGPA (P=0.013, OR 4.79, 95%CI 1.71-13.4).

With respect to IRF5, rs2280714 A allele showed a tendency toward decrease in MPA, although the difference did not reach statistical significance (A allele frequency in MPA: 49.2%, controls: 55.5%, P=0.072, OR 0.78, 95%CI 0.59-1.02). No evidence for association of BLK was detected.

Conclusion:

STAT4 rs7574865 T/T was associated with MPO-ANCA positive vasculitis. Our observations suggested that STAT4 is a shared susceptibility gene for SLE, RA, SSc and AAV.


Disclosure:

A. Kawasaki,
None;

N. Inoue,
None;

C. Ajimi,
None;

I. Ito,
None;

K. E. Sada,
None;

S. Kobayashi,
None;

H. Yamada,
None;

H. Furukawa,
None;

M. Tomita,
None;

T. Sumida,
None;

S. Tohma,

Pfizer Japan lnc., Eisai Co.,Ltd, Chugai Pharmaceutical Co.,Ltd,

2;

N. Miyasaka,
None;

S. Ozaki,
None;

H. Hashimoto,
None;

H. Makino,
None;

M. Harigai,

Teijin Pharma Limited,

5;

N. Tsuchiya,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-background-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-in-a-japanese-population-association-of-stat4-with-myeloperoxidase-antineutrophil-cytoplasmic-antibody-positive-vasculi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology